Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.51 |
| ▸ | RET | P07949 | 4/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 4/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937157 | 0.89 | KIT (0.52) | KITSRCABL1RETKDR | |
| SCHEMBL29614753 | 0.87 | KIT (0.65) | KITSRCABL1RETBRAF | |
| SCHEMBL20227773 | 0.87 | KIT (0.65) | KITSRCABL1RETBRAF | |
| SCHEMBL16380144 | 0.87 | RET (0.63) | KITSRCABL1RETKDR | |
| SCHEMBL30899974 | 0.83 | NPSR1 (0.59) | KITSRCABL1RETKDR | |
| SCHEMBL30900112 | 0.83 | CYP2C9 (0.52) | KITSRCABL1RETKDR | |
| SCHEMBL2707798 | 0.83 | DDR1 (0.56) | KITABL1DDR1BRAF | |
| SCHEMBL30486109 | 0.82 | KIT (0.49) | KITSRCABL1RETKDR | |
| SCHEMBL29958927 | 0.82 | KDM4E (0.53) | KITSRCABL1RETKDR | |
| SCHEMBL17182149 | 0.80 | MKNK2 (0.53) | KITSRCABL1RETKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111757881-B | 5- (Pyrimidin-4-yl) thiazol-2-yl urea derivatives as therapeutic agents | 澳升医药公司 | 2024-05-07 | — | — | CN | claimed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | KIT 4277/4885SRC 3388/4885ABL1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.